Disclosure Of First-Time Adoption [Text Block]

Hyloris Pharmaceuticals SA - Filing #5880974

Concept As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
As at
2024-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
86,471,000 EUR
121,513,000 EUR
140,000 EUR
476,000 EUR
945,000 EUR
4,460,000 EUR
32,143,000 EUR
39,069,000 EUR
80,761,000 EUR
476,000 EUR
121,513,000 EUR
140,000 EUR
2,162,000 EUR
4,460,000 EUR
53,909,000 EUR
476,000 EUR
121,513,000 EUR
1,622,000 EUR
65,381,000 EUR
140,000 EUR
4,460,000 EUR
Comprehensive income
6,342,000 EUR
6,342,000 EUR
15,380,000 EUR
15,380,000 EUR
Profit (loss)
6,342,000 EUR
15,380,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.